55results about "Fibrinogen" patented technology

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

The present disclosure relates to a stable human platelet lysate composition; preferably a stable heparin-free human platelet lysate composition; methods for obtaining said composition and uses thereof.

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

The invention provides a preparation method and application of myofibrillar protein hydrosol, and the method comprises the following steps: uniformly dispersing myofibrillar protein in water to obtain a myofibrillar protein suspension, mixing the myofibrillar protein suspension with protein glutaminase to obtain a mixed solution A, mixing the mixed solution A with a glucan aqueous solution to carry out glycosylation reaction to obtain a mixed solution B, and carrying out freeze drying to obtain the myofibrillar protein hydrosol. And cooling in an ice-water bath, and storing at 4 DEG C to obtain the myofibrillar protein hydrosol. The myofibrillar protein hydrosol is used for preparing protein beverages and nasal feeding nutrient solutions. The method for preparing the myofibrillar protein hydrosol with excellent dispersity and storage stability at lower production cost under the condition that professional large-scale instruments and equipment are not needed is used for preparing protein beverages and nasal feeding nutrient solutions.

This document provides methods and materials for delivering vectors (e.g., non-viral vectors or viral vectors such as adeno-associated viral (AAV) vectors) to localized areas within a mammal (e.g., a human). For example, a fibrin hydrogel including vectors (e.g., non-viral vectors or viral vectors such as AAV vectors) can be administered directly to the retina of an eye within a mammal (e.g., a human) to deliver the vectors to the retina.

The invention relates to a freeze drying method of instant fibrinogen, and belongs to the technical field of blood product preparation. The method comprises the steps of plasma pre-fusion, centrifugal separation, FI extraction, FI precipitation, dissolution and filtration, polyethylene glycol purification and separation, S / D inactivation, ethanol purification and separation, glycine purification and separation, ultrafiltration dialysis, preparation, degerming and subpackaging, freeze-drying and capping and the like. Wherein the freeze-drying process comprises four stages of pre-freezing, primary sublimation, desorption drying and plug pressing, and finally dry heat inactivation treatment is carried out. According to the method, efficient extraction and purification of fibrinogen are achieved by accurately controlling the temperature, the time, the pH value and the component proportion of various solutions in each step, and the obtained product has good instant dissolving performance and can be used in the medical fields of clinical hemostasis, tissue repair and the like.

Provided is a protein having a hexamer structure in which two molecules of a heterotrimeric protein associate at the N-terminus side, wherein the heterotrimeric protein is composed of (1) a fibrinogen Aα chain deficient in fibrinopeptide A, (2) a fibrinogen Bβ chain deficient in fibrinopeptide B and losing the ability to bind to B knob, and (3) a fibrinogen γ chain losing the ability to bind to A knob. The protein of the present invention can be used as a carrier for imparting physiological activity to fibrin gel in a thrombin-independent manner.

The present invention provides a method for fractionating human plasma using, in some embodiments, the Cohn fractionation procedure. The improvement involves using bioactive enriched plasma as the starting material for the fractionation procedure.

To provide a method for accurately determining factor XIII activity values in finished products and intermediate products in which factor XIII is purified or concentrated compared to plasma, without being affected by sample composition while also improving the workability required to measure physical properties corresponding to factor XIII activity values by using the FXIII-GLDH method.SOLUTION: Provided is a method for determining an unknown factor XIII activity value contained in a test sample by comparing the physical properties of the test sample with those of a known reference sample. The physical properties correspond to the amount of change per unit time of NAD(P)H or NAD(P)H analogues consumed or NAD(P) or NAD(P) analogues produced in the FXIII-GLDH method. The reference sample and test sample contain fibrinogen at a concentration of 2.0 to 4.0 mg / mL.SELECTED DRAWING: Figure 1

Described herein are novel methods for fractionating and isolating platelets, platelet- and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin, and methods of using the isolated platelets, platelet and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin for regenerating tissue in a subject, treating fibrinogenemia or a clotting deficiency in a subject, treating ischemia and hypoxia, treating dry-eye syndrome, an orthopedic disorder, or a dental disorder in a subject. Also described herein are growth media for culturing mammalian (e.g., human) cells.

The application discloses a human fibrinogen high-efficiency separation device and relates to the technical field of biological medicine processing. The device comprises a tank body, a stirring mechanism and a conveying mechanism. The stirring mechanism comprises a stirring shaft and a stirring paddle. The conveying mechanism comprises a fluid channel and a liquid outlet. The stirring paddle is internally provided with a mounting cavity in communication with the fluid channel and the liquid outlet. A sliding part is slidably arranged in the mounting cavity. The device further comprises a magnetic driving assembly for driving the sliding part to reciprocatingly slide in the mounting cavity so as to extrude and spray the fluid from the liquid outlet. In the application, when the stirring paddle rotates to a specific position, the sliding part extrudes the mounting cavity under the magnetic attraction force of the permanent magnet, so that the pre-cooled ethanol is rapidly sprayed from the liquid outlet. The spraying mode makes the diffusion range of the pre-cooled ethanol in the blood plasma larger and the diffusion speed faster than those of the traditional mode, thereby avoiding the instantaneous concentration of the pre-cooled ethanol in the local part being too high, effectively preventing the denaturation of the protein in the blood plasma, avoiding the local ethanol concentration being too high and preventing the protein denaturation.

The present invention relates to platelet-binding peptides and conjugates thereof, and particles comprising these and other peptides and conjugates. Additionally, compositions and methods for using these peptides and particles are provided.

To provide: a solution having at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other proteases; and a pharmaceutical formulation comprising the solution.SOLUTION: A solution comprises: (a) fibrinogen in an amount of at least 90% of the total protein; (b) a tissue plasminogen activator in an amount of less than 50 pg / mg of the total protein; and (c) plasminogen in an amount less than 10 ng / mg of the total protein. The fibrinogen retains (i) about 90% to 100% activity after the solution is stored for at least 4 weeks at a temperature of about 0°C to about 8°C, and / or (ii) about 60% to about 70% activity after the solution is stored for 5 weeks at a temperature of about 30°C.SELECTED DRAWING: None

To provide novel marker peptides for diagnosis of pancreatic cancer.SOLUTION: A method of detecting pancreatic cancer in a subject is provided, the method comprising measuring at least either of a peptide having an amino acid sequence represented by the sequence number 1 and a peptide having an amino acid sequence represented by the sequence number 2 in a biological sample of a subject.SELECTED DRAWING: Figure 1

The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.

The invention relates to a method for separating and purifying fibrinogen with low impure protein, and belongs to the technical field of blood product production. The method comprises the following steps: preparing a raw material component I, dissolving and filtering an FI precipitate, dissolving with a dissolving solution A, and filtering to obtain a filtrate A; purifying and separating polyethylene glycol, adjusting the pH value of the filtrate A, adding polyethylene glycol to precipitate, dissolving the precipitate by using the dissolving solution B, and filtering; s / D inactivation: adding an S / D solution into the filtrate B for virus inactivation; ethanol purification and separation: adding ethanol to the inactivated solution to precipitate protein, dissolving the precipitate with a dissolving solution B, and filtering; purifying and separating glycine, adding glycine precipitation protein into the filtrate C, dissolving the precipitate by using the dissolving solution C, and filtering; carrying out ultrafiltration dialysis, and dialyzing and concentrating the filtrate D; preparation: diluting the stock solution to a proper concentration; the semi-finished product is subpackaged, freeze-dried and subjected to dry heat inactivation treatment. The method can effectively remove impure proteins, improve the purity of fibrinogen and ensure the product safety.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

The present invention relates to a method for producing a fibrinogen preparation from a plasma-derived fibrinogen-containing source. The method includes the steps of providing a liquid phase containing plasma fibrinogen; contacting the liquid phase with a cation exchange chromatography material under conditions conducive to binding of fibrinogen, wherein the liquid phase has a pH in the range of pH 5.6 to pH 7.0, which is close to or higher than the pI of fibrinogen; optionally washing unbound compounds from the cation exchange chromatography material; and eluting fibrinogen from the cation exchange material. The method of the present invention is also suitable for the reduction of von Willebrand factor.

The present invention is based on fibrin-derived peptides, which are therapeutic compounds for treating inflammatory complications of virally caused diseases, such as diffuse inflammation of the endothelium, also known as systemic endotheliitis or vasculitis and related disorders. The use of fibrin-derived peptides and analogs of these compounds has resulted in surprisingly effective patient recovery.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-1990 and compositions, methods, and uses thereof.

Anemia, defined as a decreased quantity of circulating functional red blood cells, is a major source of morbidity and mortality affecting a-third of the worldwide population. As a functional component of erythrocytes hemoglobin, iron is essential for oxygen storage and transport. The liver-derived peptide hepcidin is the master regulator of iron homeostasis. During anemia, the erythroid hormone erythroferrone regulates hepcidin synthesis to ensure the proper supply of iron to the bone marrow for red blood cells synthesis. However, mounting evidence suggested that another factor may exert a similar function. Inventors identified the hepatokine FGL1 as a previously undescribed suppressor of hepcidin that is highly induced in the liver in response to hypoxia during the recovery from anemia and in thalassemic mice. Inventors demonstrated that FGL1 is a potent suppressor of hepcidin in vitro and in vivo. Deletion of Fgl1 in mice results in a blunted repression of hepcidin after bleeding. Finally, FGL1 is a BMP antagonist that directly binds BMP6 to impair the canonical BMP-SMAD signaling cascade that governs hepcidin regulation. Accordingly, the present invention relates to a FGL1 polypeptide for use in the treatment of a patient affected with an iron deficiency-related disease.

The present invention relates to mimics of post-translationally modified naturally occurring peptides, wherein said peptide mimics bind to a peptide-binding groove of human leukocyte antigen (HLA) molecules to the same extent as the naturally occurring post-translationally modified peptide, wherein said peptide mimics are recognized by T cells to the same extent as the naturally occurring post-translationally modified peptide, and additionally wherein said peptide mimics have a three-dimensional structure substantially identical to said post-translationally modified naturally occurring peptide. Such peptide mimics can be used alone of bound to a carrier, and have utility inter alia in methods for the treatment, alleviation and prevention of autoimmune diseases, and as components in tolerogenic vaccines.

Described herein are dosage forms of antibodies that bind fibrin γC or fibrinogen γC, methods of use, and dosage regimens thereof. In certain aspects, the antibodies and methods described herein are used for treatment of disorder or condition of the eye.

The invention belongs to the technical field of blood product preparation, and particularly relates to a method for filtering, separating and purifying human fibrinogen from plasma. The method sequentially comprises the following steps: balancing cellulose, mixing the balanced cellulose with raw material plasma, adsorbing and filtering to obtain cellulose precipitate; leaching the cellulose precipitate, soaking the cellulose precipitate in the precipitate dissolving solution, and filtering to obtain filtrate; carrying out first ion exchange chromatography on the filtrate; and carrying out secondary ion exchange chromatography to obtain a protein solution with fibrinogen purity of more than 80%. According to the technical scheme, the technical problems that in the prior art, the process steps of purifying and enriching the human fibrinogen from the plasma cryoprecipitate are tedious, and the utilization rate of the human fibrinogen is not ideal can be solved. According to the cryoprecipitated protein solution prepared by the method, VIII factor, vWF factor and fibrinogen products can be separated at the same time through chromatography, the utilization rate of plasma protein is improved, and the method has ideal popularization and application prospects.

The invention provides a separation and purification method of platelets and application of the platelets obtained through separation and purification in PRP or PRF. The method comprises the following steps: carrying out chemical cross-linking on an anti-erythrocyte antibody and an anti-leukocyte antibody to prepare an antibody compound, incubating the antibody compound and a blood sample to obtain a mixed solution, centrifuging, collecting supernate, and removing parenchyma cells and agglomerates to obtain the platelets. The platelet in the blood sample is separated and purified by using the method provided by the invention, the recovery rate of the platelet is greater than or equal to 92%, the activity is improved by more than 30% compared with that of a centrifugal method, the residual leukocyte is less than 1 * 10 < 6 > / mL, the residual erythrocyte is less than 5 * 10 < 7 > / mL, the clinical infusion standard is reached, the separation and purification operation steps are simple, the whole process time is less than or equal to 20 minutes, the platelet separation and purification efficiency is improved, and the cost is reduced. And the cost is reduced by more than 50%. The PRP or PRF prepared from the platelets separated and purified by the method provided by the invention can be applied to the fields of department of stomatology, maxillofacial surgery, orthopedics, plastic surgery and the like.

This document provides methods that can treat and / or prevent pneumothorax. For example, this document provides methods for delivering an aerosolized agent to reduce air leakage at a site in a respiratory tract of patient.

The invention relates to a preparation process for extracting human fibrinogen from a component I, and belongs to the technical field of blood products. The process comprises the following steps: dissolving an FI precipitate in a dissolving solution A containing sodium citrate, lysine hydrochloride and heparin sodium, and filtering to obtain a filtrate A; adding PEG (Polyethylene Glycol) into the filtrate A until the final concentration is 5%, purifying and separating, collecting PEG precipitate, dissolving and filtering to obtain filtrate B; adding polysorbate 80 and tributyl phosphate into the filtrate B to carry out S / D inactivation; cooling the inactivated liquid, adding an ethanol solution for purification and separation, collecting the precipitate, and dissolving to obtain a filtrate C; adding glycine into the filtrate C until the final concentration is 1.8 mol / L, performing purification and separation, collecting precipitates, and dissolving to obtain filtrate D; performing ultrafiltration dialysis on the filtrate D to obtain a stock solution; and diluting the stock solution to a proper concentration, sterilizing, filtering, sub-packaging, freeze-drying, and carrying out dry heat inactivation treatment to obtain a finished product. The method is simple in process and low in cost, and the prepared human fibrinogen is high in purity, good in safety and suitable for clinical hemostasis and tissue repair.

A preparation method for human fibrinogen, in which a component I precipitate is used as a raw material, a specific solvent is used in combination with a low-temperature ethanol method to prepare a human fibrinogen bulk solution, and virus inactivation is performed by combining an S / D virus inactivation method and a dry heat virus inactivation method, thereby further guaranteeing the safety of the human fibrinogen. The prepared human fibrinogen has high purity and high reconstitution speed, a reconstitution solution is clear and only slightly opalescent, and the coagulation time is short.

Disclosed are compositions comprised of fibrinogen, Factor VIII, and a positively charged amino acid, wherein the ratio of the positively charged amino acid to Factor VIII ranges from above 1.4 to below about 8.3 mg / IU, respectively, the compositions being for use e.g., for intravenous administration. Further disclosed are methods for the preparation of the compositions.